Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
April 2025 in “Journal of Cosmetic Dermatology” Azathioprine is a safe and effective long-term treatment for severe alopecia areata, significantly improving hair regrowth.
January 2025 in “The Journal of Dermatology” Certain patient traits can predict better hair regrowth with baricitinib in severe alopecia areata.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
November 2024 in “Fizioterapevt (Physiotherapist)” High-intensity phototechnology, especially with other treatments, effectively improves quality of life for diffuse alopecia patients.
September 2024 in “The Italian Journal of Pediatrics/Italian journal of pediatrics” COVID-19 vaccination may be linked to MIS-C in children, highlighting the need for quick diagnosis and treatment.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
August 2024 in “Frontiers in Public Health” Alopecia Areata severely impacts mental health, causing anxiety and depression, affecting quality of life.
July 2024 in “Journal of Investigative Dermatology” Machine learning can use blood tests to help predict moderate-to-severe alopecia areata.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
March 2024 in “Clinical and experimental dermatology” Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.
Low-level laser therapy may help uninfected cells but has different effects on coronavirus-infected cells.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
November 2023 in “Вопросы современной педиатрии” Genetic testing can diagnose hair loss linked to DSG4 gene variants.
November 2023 in “Journal of Investigative Dermatology” The study identified key immune cell differences between mild and severe alopecia areata.
October 2023 in “Journal of the Endocrine Society” Joint replacement surgery normalized high alkaline phosphatase levels in a patient with severe osteoarthritis.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
July 2023 in “Anais Brasileiros de Dermatologia” Mesalazine showed limited effectiveness in treating children with severe alopecia areata.
June 2023 in “Dermatology and Therapy” Using fractional CO2 laser with halometasone cream works better for chronic hand eczema than just the cream, improving symptoms and quality of life with fewer relapses.
January 2023 in “Annals of dermatology/Annals of Dermatology” A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.
October 2021 in “Case Reports in Veterinary Medicine” The dog died from myxedema coma linked to severe atherosclerosis and thyroid issues.
June 2020 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Researchers found a specific T cell receptor linked to severe drug reactions like Stevens-Johnson syndrome when patients take carbamazepine.
January 2020 in “Indian Journal of Forensic Medicine & Toxicology” Oral cyclosporine is an effective and safe treatment for severe alopecia areata.
December 2013 in “American journal of transplantation” The patient improved after antiviral treatment for a viral infection.